Scan to Download
One power score. Smarter investment decisions
Aura Biosciences Inc
AURA6.260USD
+0.160+2.62%
收盘 09/18, 16:00（美东）报价延迟15分钟
0.000USD0.000盘前交易 09/19, 09:30 (美东)
388.56M总市值
亏损市盈率 TTM
单季报
单季报+年报
单季报
年报
YOY
隐藏空白行
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2020Q4
FY2020Q3
营业费用
25.71%28.61M
30.13%29.04M
12.20%27.81M
13.39%23.23M
12.26%22.76M
14.76%22.31M
40.71%24.78M
27.61%20.49M
46.76%20.28M
51.78%19.44M
51.48%17.61M
80.49%16.05M
--13.82M
--12.81M
136.85%11.63M
144.97%8.89M
--4.91M
--3.63M
研发费用
35.56%22.88M
36.89%23.34M
10.13%22.33M
10.42%17.04M
11.63%16.88M
18.38%17.05M
54.12%20.28M
36.62%15.43M
58.99%15.12M
74.06%14.40M
64.92%13.16M
77.42%11.29M
--9.51M
--8.28M
125.20%7.98M
123.33%6.37M
--3.54M
--2.85M
折旧摊销及损耗
-4.15%300.00K
-1.96%300.00K
-7.41%300.00K
-21.75%313.00K
4.33%313.00K
-6.71%306.00K
0.31%324.00K
32.45%400.00K
1.35%300.00K
28.13%328.00K
40.43%323.00K
39.81%302.00K
--296.00K
--256.00K
1.77%230.00K
-6.90%216.00K
--226.00K
--232.00K
营业利润
-25.71%-28.61M
-30.13%-29.04M
-12.20%-27.81M
-13.39%-23.23M
-12.26%-22.76M
-14.76%-22.31M
-40.71%-24.78M
-27.61%-20.49M
-46.76%-20.28M
-51.78%-19.44M
-51.48%-17.61M
-80.49%-16.05M
---13.82M
---12.81M
-136.85%-11.63M
-144.97%-8.89M
---4.91M
---3.63M
净非营业利息收入（费用）
出售证券收益
----
----
----
----
----
----
----
----
----
----
--0.00
---9.00K
----
----
----
----
----
----
特殊收入（费用）
----
----
----
----
----
----
----
----
----
----
----
----
--61.00K
---44.00K
-500.00%-12.00K
--52.00K
--3.00K
--0.00
-固定资产出售收益
----
----
-100.00%0.00
----
----
----
--208.00K
----
----
--0.00
--0.00
---313.00K
----
----
--0.00
--0.00
--0.00
--0.00
其他非经营性收入（费用）
-38.46%-36.00K
25.00%-24.00K
-42.31%-37.00K
-400.00%-25.00K
18.75%-26.00K
-146.15%-32.00K
-225.00%-26.00K
28.57%-5.00K
-540.00%-32.00K
-160.00%-13.00K
---8.00K
---7.00K
---5.00K
---5.00K
----
----
----
----
税前利润
-32.62%-26.97M
-39.70%-27.46M
-17.35%-25.81M
-13.43%-21.00M
-11.14%-20.34M
-12.56%-19.66M
-32.82%-21.99M
-16.42%-18.51M
-35.87%-18.30M
-36.08%-17.47M
-42.33%-16.56M
-79.92%-15.90M
---13.47M
---12.84M
-137.09%-11.63M
-143.40%-8.84M
---4.91M
---3.63M
所得税
--48.00K
-60.87%18.00K
-82.48%24.00K
--43.00K
--0.00
--46.00K
--137.00K
----
----
----
----
----
----
----
----
----
----
----
除税后利润
-32.86%-27.02M
-39.47%-27.48M
-16.73%-25.83M
-13.67%-21.04M
-11.14%-20.34M
-12.82%-19.71M
-33.65%-22.13M
-16.42%-18.51M
-35.87%-18.30M
-36.08%-17.47M
-42.33%-16.56M
-79.92%-15.90M
---13.47M
---12.84M
-137.09%-11.63M
-143.40%-8.84M
---4.91M
---3.63M
持续经营利润
-32.86%-27.02M
-39.47%-27.48M
-16.73%-25.83M
-13.67%-21.04M
-11.14%-20.34M
-12.82%-19.71M
-33.65%-22.13M
-16.42%-18.51M
-35.87%-18.30M
-36.08%-17.47M
-42.33%-16.56M
-79.92%-15.90M
---13.47M
---12.84M
-137.09%-11.63M
-143.40%-8.84M
---4.91M
---3.63M
归属于母公司的净利润
-32.86%-27.02M
-39.47%-27.48M
-16.73%-25.83M
-13.67%-21.04M
-11.14%-20.34M
-12.82%-19.71M
-33.65%-22.13M
-16.42%-18.51M
-35.87%-18.30M
-36.08%-17.47M
-27.88%-16.56M
-27.15%-15.90M
---13.47M
---12.84M
-84.17%-12.95M
-124.16%-12.51M
---7.03M
---5.58M
优先股派息
----
----
----
----
----
----
----
----
----
----
-100.00%0.00
----
----
--0.00
-38.09%1.31M
88.30%3.67M
--2.12M
--1.95M
归属于普通股东的净利润
-32.86%-27.02M
-39.47%-27.48M
-16.73%-25.83M
-13.67%-21.04M
-11.14%-20.34M
-12.82%-19.71M
-33.65%-22.13M
-16.42%-18.51M
-35.87%-18.30M
-36.08%-17.47M
-27.88%-16.56M
-27.15%-15.90M
---13.47M
---12.84M
-84.17%-12.95M
-124.16%-12.51M
---7.03M
---5.58M
基本每股收益
-13.47%-0.47
-37.59%-0.55
-4.37%-0.52
12.61%-0.42
15.09%-0.41
13.80%-0.40
4.19%-0.50
10.75%-0.48
-4.99%-0.48
-5.21%-0.46
-16.80%-0.52
-26.88%-0.54
---0.46
---0.44
-78.95%-0.44
-118.01%-0.43
---0.25
---0.20
稀释每股收益
-13.47%-0.47
-37.59%-0.55
-4.37%-0.52
12.61%-0.42
15.09%-0.41
13.80%-0.40
4.19%-0.50
10.75%-0.48
-4.99%-0.48
-5.21%-0.46
-16.80%-0.52
-26.88%-0.54
---0.46
---0.44
-78.95%-0.44
-118.01%-0.43
---0.25
---0.20
每股派息
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
货币单位
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
审计意见
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
